Three stakeholders raise concerns and suggest improvements to an FDA proposed rule on product jurisdiction.
FDA releases its latest batch of Warning Letters that include Baxter (Claris Injectables Ltd.) and bB BioChem Laboratories.
FDA commissioner Scott Gottlieb outlines a new agency draft guidance on approaches to expanding approval of non-prescription drugs.
Federal Register notice: FDA announces the renewal of the Science Board for an additional two years.
Federal Register notice: FDA seeks comments on an information collection extension entitled Registration of Producers of Drugs and Listing of Drugs in...
A Tufts Center for the Study of Drug Development Report says that protocol design changes since 2001 have increased clinical costs and inefficiencies.
FDA warns Baxters Claris Injectables about CGMP violations in its production of finished pharmaceuticals at its India facility.
FDA releases a summary of points covered at a 4/16 workshop on clinical trial inclusion and exclusion criteria.